Skip to main content

Drug Interactions between fesoterodine and oritavancin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

fesoterodine oritavancin

Applies to: fesoterodine and oritavancin

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of fesoterodine's active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme. Following induction of CYP450 3A4 with rifampin 600 mg once a day, 5-hydroxymethyl tolterodine peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 70% and 75%, respectively, after oral administration of fesoterodine 8 mg. The effects of less potent CYP450 3A4 inducers were not examined.

MANAGEMENT: Caution is advised when fesoterodine is used with CYP450 3A4 inducers. The possibility of diminished therapeutic effects should be considered.

Drug and food interactions

Moderate

fesoterodine food

Applies to: fesoterodine

Grapefruit juice may increase the levels of fesoterodine in your body. Let your doctor know if you experience excessive drowsiness, dizziness, irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, gastrointestinal upset, or constipation while taking fesoterodine. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer